No profile data available.
Precision BioSciences, Inc. (DTIL) is a healthcare company in the hepatic treatment pharmaceuticals industry, based in Durham, United States, with about 67 full-time employees.
It reported revenue of $34.26 million for fiscal year 2025, down 50.1% from fiscal year 2024, and net income of -$45.72 million. Its market capitalization was $120.84 million as of December 4, 2025.
Figures from company filings and market data; latest fiscal year ended December 31, 2025; market data as of December 4, 2025.
, a clinical stage gene editing company, develops in vivo gene editing therapies for gene edits, including gene insertion, excision, and elimination in the United States. The company offers ARCUS, a genome editing platform for DNA genome insertion, removal, and repair. 3243 associated mitochondrial myopathy.
Precision BioSciences reported $34.26 million in revenue for fiscal year 2025, down 50.1% from $68.70 million in fiscal year 2024.
$120.84 million as of December 4, 2025.
Listed companies of a similar size in the same industry (hepatic treatment pharmaceuticals) include Monopar Therapeutics Inc. (MNPR), Galectin Therapeutics Inc. (GALT), Enanta Pharmaceuticals, Inc. (ENTA), Aligos Therapeutics, Inc. (ALGS).